Zoster Vaccine Market to Reach $9.1 Billion by 2033; Increasing Cases of Herpes Zoster Drives the Market’s Growth – Yahoo Finance

The Brainy Insights

The market for zoster vaccines has increased due to the rising incidence of chickenpox in North America. Key players evolving in the zoster vaccine market are Merck & Co., Inc., Changchun BCHT Biotechnology Co, Vaccitech, Pfizer Inc, Jiangsu Recbio Technology Co., Ltd, GSK plc, SK chemicals, Geneone Life Science, CanSinoBIO, and Curevo Inc.

Newark, July 29, 2024 (GLOBE NEWSWIRE) -- The Brainy Insights estimates that the USD 4.2 billionzoster vaccine market will reach USD 9.1 billion by 2033. The zoster vaccine market is driven by people's increasing understanding of how important vaccination is to preventing shingles. The global ageing population also fuels the market's expansion because shingles are more common in elderly persons. As an example, seroprevalence research conducted on Indian volunteers revealed that by the time they were 40 years old, over 90% of the participants carried this virus, making them susceptible to shingles. For individuals over 50, the Shingrix vaccination has been authorised to prevent both shingles and post-herpetic neuralgia. In addition, new and more potent vaccines and technological developments in vaccinations are anticipated to spur market expansion. Based on these indications, the market for zoster vaccines is expected to rise steadily over the next several years.

Request market scope and parent market analysis sample PDF: https://www.thebrainyinsights.com/enquiry/sample-request/14423

Key Insight of the Global Zoster Vaccine Market

North America will account for the largest market size during the forecast period.

The region's market is mostly driven by large players in North America, advantageous reimbursement practices, and high vaccination rates. In the United States, about 35% of eligible individuals have received vaccinations, whereas in Canada, over 20% do so. Additionally, public awareness and the region's recommendation for immunisation against the disease drive the market's growth over the projection period. Because of Shingrix's superior efficacy over Zostavax, the United States and Canada advise using it to prevent shingles in the elderly population.

The shingrix segment dominated the market, with a revenue of USD 1.76 billion.

The shingrix segment dominated the market, with the most significant revenue of USD 1.76 billion. The segment's growth can be ascribed to rising illness awareness and the approval of shingrix vaccines in different areas. For example, in May 2019, the National Medical Products Administration in China licensed shingrix as a shingles preventive.

Story continues

The recombinant vaccine segment dominated the market, with the most significant revenue of USD 2.43 billion.

The recombinant vaccine segment dominated the market, with the most significant revenue of USD 2.43 billion. The widespread use of shingrix throughout North America and Europe and the recombinant vaccine's great effectiveness in protecting adults against diseases drive the segment's growth.

Get a comprehensive report summary describing the market size and forecast: https://www.thebrainyinsights.com/enquiry/speak-to-analyst/14423

Market Dynamics:

Drivers: Increasing cases of herpes zoster worldwide

The ageing population compromised immune systems, and rising rates of chronic illnesses like HIV and cancer will all contribute to the global rise in the prevalence of herpes zoster disease, which will fuel the zoster vaccine market's expansion. Because more individuals are becoming aware of how important immunisation is to preventing shingles, there will likely be a rise in demand for zoster vaccine in the upcoming years.

Restraint: Limited vaccine uptake

In certain places, immunisation rates remain quite low despite strong recommendations. Misinformation, vaccination hesitancy, and adverse effect concerns impede market expansion.

Some of the major players operating in the zoster vaccine market are:

Merck & Co., Inc. Changchun BCHT Biotechnology Co Vaccitech Pfizer Inc Jiangsu Recbio Technology Co., Ltd GSK plc SK chemicals Geneone Life Science CanSinoBIO Curevo Inc

Key Segments cover in the market:

By Product:

SKYZoster Zostavax Shingrix

By Vaccine Type:

Live Attenuated Vaccine Recombinant Vaccine

Interested in Procure Data? Visit: https://www.thebrainyinsights.com/buy-now/14423/single

About the report:

The global zoster vaccine market is analyzed based on value (USD billion). All the segments have been analyzed on a worldwide, regional, and country basis. The study includes the analysis of more than 30 countries for each part. The report offers an in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining critical insight into the market. The study includes Porter's five forces model, attractiveness analysis, raw material analysis, supply, and demand analysis, competitor position grid analysis, distribution, and marketing channels analysis.

About The Brainy Insights:

The Brainy Insights is a market research company, aimed at providing actionable insights through data analytics to companies to improve their business acumen. We have a robust forecasting and estimation model to meet the clients' objectives of high-quality output within a short span of time. We provide both customized (clients' specific) and syndicate reports. Our repository of syndicate reports is diverse across all the categories and sub-categories across domains. Our customized solutions are tailored to meet the clients' requirement whether they are looking to expand or planning to launch a new product in the global market.

Contact Us

Avinash D Head of Business Development Phone: +1-315-215-1633 Email: sales@thebrainyinsights.com Web: http://www.thebrainyinsights.com

See more here:

Zoster Vaccine Market to Reach $9.1 Billion by 2033; Increasing Cases of Herpes Zoster Drives the Market's Growth - Yahoo Finance